search
Back to results

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Primary Purpose

Alzheimer Disease

Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Bapineuzumab 0.5 mg/kg
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease focused on measuring antibody, immunotherapy

Eligibility Criteria

51 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject has completed study 3133K1-3001 (Week 78) and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
  • Mini-Mental Status Examination (MMSE) >=10 at screening
  • Caregiver able to attend all clinic visits with subject

Exclusion Criteria:

  • Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.
  • Any significant brain MRI abnormality.
  • Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening

Sites / Locations

  • University Of Alabama at Birmingham
  • UAB Center for Psychiatric Medicine
  • University of Alabama at Birmingham
  • University of Alabama-Birmingham
  • Dedicated Clinical Research
  • Banner Alzheimer's Institute
  • Banner Good Samaritan Medical Center (Imaging
  • Jeffrey S. Gitt
  • Hope Research Institute
  • Clinical Trials, Inc.
  • San Francisco Clinical Research Center
  • Alpine Clinical Research Center, Inc.
  • Associated Neurologist, PC
  • Mile High Research Center
  • Associated Neurologists of Southern Connecticut, P.C.
  • Bendheim Infusion Center, Greenwich Hospital
  • Center for Healthy Aging, Greenwich Hospital
  • Research Center for Clinical Studies, Inc.
  • JEM Research LLC
  • Medical Specialists of the Palm Beaches
  • Brain Matters Research
  • Compass Research, LLC
  • Palm Beach Neurological Center, Advanced Research Consultants, Inc.
  • Neurostudies, Inc
  • Southwest Florida Infusion Care, Inc.
  • Roskamp Institute
  • USF Health Byrd Alzheimer's Institute
  • Neuroscience Research Institute, LLC
  • Neurostudies.net
  • Alexian Brothers Neurosciences Institute Clinical Research
  • Southern Illinois University School of Medicine Department
  • Lake Charles Clinical Trials
  • Neuroscience Research of the Berkshires
  • Springfield Neurology Associates, LLC
  • Michigan State University
  • Michigan State University
  • Neurological Research Center of Hattiesburg Clinic
  • The Center for Pharmaceutical Research, P.C.
  • Memory Enhancement Center of America, Inc.
  • Alzheimer's Research Corp./Merician Institute for Aging
  • Toms River X-Ray, CT & MRI
  • MDR
  • Neurological Care of Central New York
  • Carolina Neuropsychological Services, Inc.
  • Healthsouth Blue Ridge Surgery Center
  • Raleigh Neurology Associates
  • Wake Radiology Associates
  • Ohio State Unviersity
  • Summit Research Network(Oregon) Inc.
  • Providence Brain Institute-Cognitive Assessment Clinic
  • Providence Brain Institute
  • Abington Neurological Associates
  • Abington Neurological Assoc
  • Bington Memorial Hospital
  • Clinical Trial Center, LLC
  • Thomas Jefferson University Hospital
  • Thomas Jefferson University
  • Rhode Island Mood and Memory Research Institute
  • Medical University of South Carolina Hospitals and Clinics
  • Medical University of South Carolina
  • Medical University of South Carolina
  • Texas Neurology, P.A.
  • Innovative Clinical Trials
  • Integra Clinical Research, LLC
  • Vista Infusions
  • Inventive Infusion Solutions
  • Hospital Italiano de Buenos Aires
  • Gosford Hospital; Pharmacy Dept
  • Hornsby Hospital
  • Royal Adelaide Memory Trials Centre
  • Memory Unit 5C, Department of Neurology
  • The Queen Elizabeth Hospital
  • Heidelberg Repatriation Hospital
  • Hollywood Hospital; Pharmacy Dept
  • The McCusker Foundation for Alzheimer's Disease Research
  • ZNA Middelheim
  • AZ Sint-Jan Brugge-Oostende AV
  • Cliniques Universitaires St Luc
  • Universitair Ziekenhuis Gasthuisberg
  • H.-Hartziekenhuis Roeselare-Menen
  • Psicomedica Research Group
  • Ita-Suomen Yliopisto
  • University of Turku/CRST
  • CHU Hôpital Pellegrin-Tripode
  • Hopital Neurologique
  • CHU de Caen
  • Hôpitaux Civils de Colmar
  • CHU de Dijon
  • Hôpital Roger Salengro
  • Hôpital la Timone
  • Hôpital la Timone
  • CHU Hôpital Gui de Chaulliac
  • CHU Nord - Hôpital Guillaume et René Laënnec
  • Hôpital Cimiez
  • Hôpital Pitié-Salpétrière
  • CHU La Milétrie
  • C.H.U de Reims
  • Department de Radiologie et d'Imagerie Medicale, Hopital Pontchaillou
  • CHRU Hôtel Dieu
  • Centre Hospitalier Universitaire Charles Nicolle
  • Hôpital Purpan
  • CHU Purpan - Hôpital Casselardit
  • Sezione di Neurologia - Dipartimento di Neuroscienze
  • Dipartimento di Neuroscienze,
  • Fondazione IRCCS- Istituto Neurologico Carlo Besta
  • Unita' Operativa C - Riabilitazione Neurologica
  • Nagoya City University Hospital
  • Yachiyo Hospital
  • National Hospital Organization Chiba-East Hospital
  • Kashiwado Hospital
  • Nippon Medical School Chiba Hokusoh Hospital
  • National Hospital Organization Kokura Medical Center
  • Maebashi Red Cross Hospital
  • Gunma University Hospital
  • Shinozuka Hospital
  • National Hospital Organization Hiroshima-nishi Medical Ctr.
  • Kobe University Hospital
  • Kagawa University Hospital
  • Nippon Medical School Musashi Kosugi Hospital
  • Rakuwakai Otowa Hospital
  • National Hospital Organization Minami-Kyoto Hospital
  • National Hospital Organization Maizuru Medical Center
  • National Hospital Organization Matsumoto Medical Center
  • National Hospital Organization Niigata National Hospital
  • Okayama University Hospital
  • National Hospital Organization Minami-Okayama Medical Center
  • Osaka City University Hospital
  • Kansai Medical University Takii Hospital
  • Juntendo University Hospital
  • Juntendo Tokyo Koto Geriatric Medical Center
  • Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp
  • Tokyo Medical University Hospital
  • Tokyo Medical University Hachioji Medical Center
  • National Hospital Organization Tokyo National Hospital
  • Geriatry
  • Jeroen Bosch Ziekenhuis
  • Vrije Universiteit Medisch Centrum
  • Medisch Centrum Leeuwarden
  • The Memory Clinic Limited
  • Christchurch Hospital
  • Signet Research
  • Pallmed Spolka z o.o.
  • MCD Voxel
  • NZOZ Neuro-kard
  • Pracownia Rezonansu Magnetycznego
  • SP ZOZ Szpital Wolski
  • Samodzielny Publiczny Centralny Szpital Kliniczny
  • Hospital Fernando da Fonseca
  • Hospitais Da Universidade De Coimbra
  • Hospital Santa Maria
  • Univerzitna nemocnica Bratislava
  • Vseobecna nemocnica Rimavska Sobota
  • Boithuso Caregivers
  • The Osteoporosis and Memory Centre
  • St Augustine's Medical Centre 2
  • Hospital General Universitario de Elche
  • Hospital Mutua de Terrasa
  • Hospital Virgen del Puerto
  • Hospital Universitario Son Espases
  • CLONUS
  • Hospital del Mar
  • Fundacio ACE Institut Catala de Neurociences Aplicades
  • Clinica CIMA
  • Hospital Divino Valles
  • Hospital de la Princesa
  • Hospital Clinico San Carlos
  • Hospital Universitario La Paz
  • Hospital Universitario Virgen de la Arrixaca
  • Malmo University Hospital
  • Minnes- och geriatrikmottagningen
  • Memory Clinic Neuro-Psychologie Zentrum
  • Memory Service North, Grenoside Grange Hospital
  • Llandough Hospital, Universtity Hospital of Wales
  • MAC UK Neuroscience Ltd.
  • Clinical Investigation and Research Unit (CIRU)
  • Glasgow Memory Clinic
  • Dept. of Neurosciences Charing Cross Hospital
  • The Doctors Laboratory Ltd.
  • Newcastle General Hospital
  • Northampton General Hospital
  • Royal Hallamshire Hospital
  • Victoria Hospital
  • Alliance Medical

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bapineuzumab 0.5 mg/kg

Arm Description

Outcomes

Primary Outcome Measures

Number of Participants Reporting a Serious Adverse Event
Safety was measured according to standard adverse event collection as described in the Adverse Event Section of the Results. Complete tables of events are provided there.

Secondary Outcome Measures

Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4)constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8 remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4)constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8)remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
The DAD measures instrumental and basic activities of daily living in AD participants. The DAD is administered to the participant's caregiver in the form of an interview. The performance of basic activities of daily living is evaluated in 10 aspects including hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The caregiver answers 40 questions as yes, no, or not applicable. A one-point score was assigned to each question if the answer is "yes" and a zero score was assigned if the answer is "no". For questions answered as "not applicable", no score will be assigned. The DAD total score was calculated as the total number of questions answered as "yes" divided by the total number of questions answered as "yes" or "no", times 100. The DAD score can range from 0 to 100, with higher scores indicating better function. A positive change indicates improvement from baseline.
Change From Extension Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
The DAD measures instrumental and basic activities of daily living in AD participants. The DAD is administered to the participant's caregiver in the form of an interview. The performance of basic activities of daily living is evaluated in 10 aspects including hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The caregiver answers 40 questions as yes, no, or not applicable. A one-point score was assigned to each question if the answer is "yes" and a zero score was assigned if the answer is "no". For questions answered as "not applicable", no score will be assigned. The DAD total score was calculated as the total number of questions answered as "yes" divided by the total number of questions answered as "yes" or "no", times 100. The DAD score can range from 0 to 100, with higher scores indicating better function. A positive change indicates improvement from baseline.
Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/ aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/ indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity(1=Mild to 3=Severe),frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). The NPI total score ranges from 0 to 144 with higher NPI scores indicate greater impairment. A negative change indicates improvement from baseline.
Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/ aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/ indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity(1=Mild to 3=Severe),frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). The NPI total score ranges from 0 to 144 with higher NPI scores indicate greater impairment. A negative change indicates improvement from baseline.
Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. The MMSE total score can range from 0 to 30, with lower scores indicating a greater degree of impairment. A positive change indicates improvement from baseline.
Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. The MMSE total score can range from 0 to 30, with lower scores indicating a greater degree of impairment. A positive change indicates improvement from baseline.

Full Information

First Posted
October 16, 2009
Last Updated
November 30, 2015
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00998764
Brief Title
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
Official Title
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Terminated
Why Stopped
The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
Study Start Date
December 2009 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
antibody, immunotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
494 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bapineuzumab 0.5 mg/kg
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Bapineuzumab 0.5 mg/kg
Other Intervention Name(s)
AAB-001
Intervention Description
I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
Primary Outcome Measure Information:
Title
Number of Participants Reporting a Serious Adverse Event
Description
Safety was measured according to standard adverse event collection as described in the Adverse Event Section of the Results. Complete tables of events are provided there.
Time Frame
Up to Week 195
Secondary Outcome Measure Information:
Title
Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78
Description
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4)constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8 remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Time Frame
Base Study Baseline, Weeks 13, 26, 39, 52 and 78
Title
Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.
Description
The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4)constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8)remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.
Time Frame
Base Study Baseline, Weeks 13, 26, 39, 52 and 78
Title
Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
Description
The DAD measures instrumental and basic activities of daily living in AD participants. The DAD is administered to the participant's caregiver in the form of an interview. The performance of basic activities of daily living is evaluated in 10 aspects including hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The caregiver answers 40 questions as yes, no, or not applicable. A one-point score was assigned to each question if the answer is "yes" and a zero score was assigned if the answer is "no". For questions answered as "not applicable", no score will be assigned. The DAD total score was calculated as the total number of questions answered as "yes" divided by the total number of questions answered as "yes" or "no", times 100. The DAD score can range from 0 to 100, with higher scores indicating better function. A positive change indicates improvement from baseline.
Time Frame
Base Study Baseline, Weeks 13, 26, 39, 52 and 78
Title
Change From Extension Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.
Description
The DAD measures instrumental and basic activities of daily living in AD participants. The DAD is administered to the participant's caregiver in the form of an interview. The performance of basic activities of daily living is evaluated in 10 aspects including hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The caregiver answers 40 questions as yes, no, or not applicable. A one-point score was assigned to each question if the answer is "yes" and a zero score was assigned if the answer is "no". For questions answered as "not applicable", no score will be assigned. The DAD total score was calculated as the total number of questions answered as "yes" divided by the total number of questions answered as "yes" or "no", times 100. The DAD score can range from 0 to 100, with higher scores indicating better function. A positive change indicates improvement from baseline.
Time Frame
Base Study Baseline, Weeks 13, 26, 39, 52 and 78
Title
Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.
Description
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/ aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/ indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity(1=Mild to 3=Severe),frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). The NPI total score ranges from 0 to 144 with higher NPI scores indicate greater impairment. A negative change indicates improvement from baseline.
Time Frame
Base Study Baseline, Weeks 26, 52 and 78
Title
Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.
Description
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/ aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/ indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity(1=Mild to 3=Severe),frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). The NPI total score ranges from 0 to 144 with higher NPI scores indicate greater impairment. A negative change indicates improvement from baseline.
Time Frame
Base Study Baseline, Weeks 26, 52 and 78
Title
Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.
Description
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. The MMSE total score can range from 0 to 30, with lower scores indicating a greater degree of impairment. A positive change indicates improvement from baseline.
Time Frame
Base Study Baseline, Weeks 6, 19, 32, 45 and 78
Title
Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.
Description
MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. The MMSE total score can range from 0 to 30, with lower scores indicating a greater degree of impairment. A positive change indicates improvement from baseline.
Time Frame
Base Study Baseline, Weeks 6, 19, 32, 45 and 78

10. Eligibility

Sex
All
Minimum Age & Unit of Time
51 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has completed study 3133K1-3001 (Week 78) and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease Mini-Mental Status Examination (MMSE) >=10 at screening Caregiver able to attend all clinic visits with subject Exclusion Criteria: Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response. Any significant brain MRI abnormality. Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
University Of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35249
Country
United States
Facility Name
UAB Center for Psychiatric Medicine
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of Alabama-Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Dedicated Clinical Research
City
Goodyear
State/Province
Arizona
ZIP/Postal Code
85395
Country
United States
Facility Name
Banner Alzheimer's Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Banner Good Samaritan Medical Center (Imaging
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Jeffrey S. Gitt
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85032
Country
United States
Facility Name
Hope Research Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85050
Country
United States
Facility Name
Clinical Trials, Inc.
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
San Francisco Clinical Research Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94109
Country
United States
Facility Name
Alpine Clinical Research Center, Inc.
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80304
Country
United States
Facility Name
Associated Neurologist, PC
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80304
Country
United States
Facility Name
Mile High Research Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Associated Neurologists of Southern Connecticut, P.C.
City
Fairfield
State/Province
Connecticut
ZIP/Postal Code
06824
Country
United States
Facility Name
Bendheim Infusion Center, Greenwich Hospital
City
Greenwich
State/Province
Connecticut
ZIP/Postal Code
06830
Country
United States
Facility Name
Center for Healthy Aging, Greenwich Hospital
City
Greenwich
State/Province
Connecticut
ZIP/Postal Code
06830
Country
United States
Facility Name
Research Center for Clinical Studies, Inc.
City
Norwalk
State/Province
Connecticut
ZIP/Postal Code
06851
Country
United States
Facility Name
JEM Research LLC
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
Medical Specialists of the Palm Beaches
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
Brain Matters Research
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33445
Country
United States
Facility Name
Compass Research, LLC
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Palm Beach Neurological Center, Advanced Research Consultants, Inc.
City
Palm Beach Gardens
State/Province
Florida
ZIP/Postal Code
33418
Country
United States
Facility Name
Neurostudies, Inc
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33952
Country
United States
Facility Name
Southwest Florida Infusion Care, Inc.
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33952
Country
United States
Facility Name
Roskamp Institute
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34234
Country
United States
Facility Name
USF Health Byrd Alzheimer's Institute
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Neuroscience Research Institute, LLC
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30046
Country
United States
Facility Name
Neurostudies.net
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30046
Country
United States
Facility Name
Alexian Brothers Neurosciences Institute Clinical Research
City
Elk Grove Village
State/Province
Illinois
ZIP/Postal Code
60007
Country
United States
Facility Name
Southern Illinois University School of Medicine Department
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62702
Country
United States
Facility Name
Lake Charles Clinical Trials
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70629
Country
United States
Facility Name
Neuroscience Research of the Berkshires
City
Pittsfield
State/Province
Massachusetts
ZIP/Postal Code
01201
Country
United States
Facility Name
Springfield Neurology Associates, LLC
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01104
Country
United States
Facility Name
Michigan State University
City
East Lansing
State/Province
Michigan
ZIP/Postal Code
48824
Country
United States
Facility Name
Michigan State University
City
East Lansing
State/Province
Michigan
ZIP/Postal Code
48848
Country
United States
Facility Name
Neurological Research Center of Hattiesburg Clinic
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
Facility Name
The Center for Pharmaceutical Research, P.C.
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64114
Country
United States
Facility Name
Memory Enhancement Center of America, Inc.
City
Eatontown
State/Province
New Jersey
ZIP/Postal Code
07724
Country
United States
Facility Name
Alzheimer's Research Corp./Merician Institute for Aging
City
Manchester
State/Province
New Jersey
ZIP/Postal Code
08759
Country
United States
Facility Name
Toms River X-Ray, CT & MRI
City
Toms River
State/Province
New Jersey
ZIP/Postal Code
08755
Country
United States
Facility Name
MDR
City
LiverPool
State/Province
New York
ZIP/Postal Code
13088
Country
United States
Facility Name
Neurological Care of Central New York
City
Liverpool
State/Province
New York
ZIP/Postal Code
13088
Country
United States
Facility Name
Carolina Neuropsychological Services, Inc.
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Healthsouth Blue Ridge Surgery Center
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Raleigh Neurology Associates
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Wake Radiology Associates
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Ohio State Unviersity
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Summit Research Network(Oregon) Inc.
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
Providence Brain Institute-Cognitive Assessment Clinic
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Providence Brain Institute
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Abington Neurological Associates
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Abington Neurological Assoc
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Bington Memorial Hospital
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
Clinical Trial Center, LLC
City
Jenkintown
State/Province
Pennsylvania
ZIP/Postal Code
19046
Country
United States
Facility Name
Thomas Jefferson University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Rhode Island Mood and Memory Research Institute
City
East Providence
State/Province
Rhode Island
ZIP/Postal Code
02914
Country
United States
Facility Name
Medical University of South Carolina Hospitals and Clinics
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29245
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Medical University of South Carolina
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Texas Neurology, P.A.
City
Dallas
State/Province
Texas
ZIP/Postal Code
75214
Country
United States
Facility Name
Innovative Clinical Trials
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Integra Clinical Research, LLC
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Vista Infusions
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Inventive Infusion Solutions
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Hospital Italiano de Buenos Aires
City
Buenos Aires
ZIP/Postal Code
C1181ACH
Country
Argentina
Facility Name
Gosford Hospital; Pharmacy Dept
City
Gosford
State/Province
New South Wales
ZIP/Postal Code
2250
Country
Australia
Facility Name
Hornsby Hospital
City
Hornsby
State/Province
New South Wales
ZIP/Postal Code
2207
Country
Australia
Facility Name
Royal Adelaide Memory Trials Centre
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Memory Unit 5C, Department of Neurology
City
Woodville South
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
Facility Name
The Queen Elizabeth Hospital
City
Woodville South
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
Facility Name
Heidelberg Repatriation Hospital
City
Heidelberg West
State/Province
Victoria
ZIP/Postal Code
3081
Country
Australia
Facility Name
Hollywood Hospital; Pharmacy Dept
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
The McCusker Foundation for Alzheimer's Disease Research
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
ZNA Middelheim
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
Facility Name
AZ Sint-Jan Brugge-Oostende AV
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Cliniques Universitaires St Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Universitair Ziekenhuis Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
H.-Hartziekenhuis Roeselare-Menen
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Facility Name
Psicomedica Research Group
City
Santiago
ZIP/Postal Code
7530193
Country
Chile
Facility Name
Ita-Suomen Yliopisto
City
Kuopio
ZIP/Postal Code
FIN-70210
Country
Finland
Facility Name
University of Turku/CRST
City
Turku
ZIP/Postal Code
FIN-20520
Country
Finland
Facility Name
CHU Hôpital Pellegrin-Tripode
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Facility Name
Hopital Neurologique
City
Bron
ZIP/Postal Code
69677
Country
France
Facility Name
CHU de Caen
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hôpitaux Civils de Colmar
City
Colmar
ZIP/Postal Code
68024
Country
France
Facility Name
CHU de Dijon
City
Dijon
ZIP/Postal Code
21000
Country
France
Facility Name
Hôpital Roger Salengro
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hôpital la Timone
City
Marseille cedex 5
ZIP/Postal Code
13385
Country
France
Facility Name
Hôpital la Timone
City
Marseille
ZIP/Postal Code
13885
Country
France
Facility Name
CHU Hôpital Gui de Chaulliac
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
CHU Nord - Hôpital Guillaume et René Laënnec
City
Nantes - Saint Herblain
ZIP/Postal Code
44093
Country
France
Facility Name
Hôpital Cimiez
City
Nice
ZIP/Postal Code
06000
Country
France
Facility Name
Hôpital Pitié-Salpétrière
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
CHU La Milétrie
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
C.H.U de Reims
City
Reims
ZIP/Postal Code
51000
Country
France
Facility Name
Department de Radiologie et d'Imagerie Medicale, Hopital Pontchaillou
City
Rennes Cedex 9
ZIP/Postal Code
35033
Country
France
Facility Name
CHRU Hôtel Dieu
City
Rennes
ZIP/Postal Code
35064
Country
France
Facility Name
Centre Hospitalier Universitaire Charles Nicolle
City
Rouen Cedex
ZIP/Postal Code
76031
Country
France
Facility Name
Hôpital Purpan
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
CHU Purpan - Hôpital Casselardit
City
Toulouse
ZIP/Postal Code
31300
Country
France
Facility Name
Sezione di Neurologia - Dipartimento di Neuroscienze
City
Ancona
ZIP/Postal Code
60020
Country
Italy
Facility Name
Dipartimento di Neuroscienze,
City
Catania
ZIP/Postal Code
95123
Country
Italy
Facility Name
Fondazione IRCCS- Istituto Neurologico Carlo Besta
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
Unita' Operativa C - Riabilitazione Neurologica
City
Roma
ZIP/Postal Code
00179
Country
Italy
Facility Name
Nagoya City University Hospital
City
Nagoya
State/Province
Aichi,
ZIP/Postal Code
467-8602
Country
Japan
Facility Name
Yachiyo Hospital
City
Aichi
ZIP/Postal Code
446-8510
Country
Japan
Facility Name
National Hospital Organization Chiba-East Hospital
City
Chiba-shi
ZIP/Postal Code
260-8712
Country
Japan
Facility Name
Kashiwado Hospital
City
Chiba
ZIP/Postal Code
260-8656
Country
Japan
Facility Name
Nippon Medical School Chiba Hokusoh Hospital
City
Chiba
ZIP/Postal Code
270-1694
Country
Japan
Facility Name
National Hospital Organization Kokura Medical Center
City
Fukuoka
ZIP/Postal Code
802-8533
Country
Japan
Facility Name
Maebashi Red Cross Hospital
City
Gunma
ZIP/Postal Code
371-0014
Country
Japan
Facility Name
Gunma University Hospital
City
Gunma
ZIP/Postal Code
371-8511
Country
Japan
Facility Name
Shinozuka Hospital
City
Gunma
ZIP/Postal Code
375-0017
Country
Japan
Facility Name
National Hospital Organization Hiroshima-nishi Medical Ctr.
City
Hiroshima
ZIP/Postal Code
739-0696
Country
Japan
Facility Name
Kobe University Hospital
City
Hyogo
ZIP/Postal Code
650-0017
Country
Japan
Facility Name
Kagawa University Hospital
City
Kagawa
ZIP/Postal Code
761-0793
Country
Japan
Facility Name
Nippon Medical School Musashi Kosugi Hospital
City
Kanagawa
ZIP/Postal Code
211-8533
Country
Japan
Facility Name
Rakuwakai Otowa Hospital
City
Kyoto
ZIP/Postal Code
607-8062
Country
Japan
Facility Name
National Hospital Organization Minami-Kyoto Hospital
City
Kyoto
ZIP/Postal Code
610-0113
Country
Japan
Facility Name
National Hospital Organization Maizuru Medical Center
City
Kyoto
ZIP/Postal Code
625-8502
Country
Japan
Facility Name
National Hospital Organization Matsumoto Medical Center
City
Nagano
ZIP/Postal Code
399-0021
Country
Japan
Facility Name
National Hospital Organization Niigata National Hospital
City
Niigata
ZIP/Postal Code
945-8585
Country
Japan
Facility Name
Okayama University Hospital
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Facility Name
National Hospital Organization Minami-Okayama Medical Center
City
Okayama
ZIP/Postal Code
701-0304
Country
Japan
Facility Name
Osaka City University Hospital
City
Osaka
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Kansai Medical University Takii Hospital
City
Osaka
ZIP/Postal Code
570-8507
Country
Japan
Facility Name
Juntendo University Hospital
City
Tokyo
ZIP/Postal Code
113-8431
Country
Japan
Facility Name
Juntendo Tokyo Koto Geriatric Medical Center
City
Tokyo
ZIP/Postal Code
136-0075
Country
Japan
Facility Name
Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp
City
Tokyo
ZIP/Postal Code
145-0065
Country
Japan
Facility Name
Tokyo Medical University Hospital
City
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
Facility Name
Tokyo Medical University Hachioji Medical Center
City
Tokyo
ZIP/Postal Code
193-0944
Country
Japan
Facility Name
National Hospital Organization Tokyo National Hospital
City
Tokyo
ZIP/Postal Code
204-8585
Country
Japan
Facility Name
Geriatry
City
's-HERTOGENBOSCH
ZIP/Postal Code
5223 GZ
Country
Netherlands
Facility Name
Jeroen Bosch Ziekenhuis
City
's-Hertogenbosch
ZIP/Postal Code
5223 GZ
Country
Netherlands
Facility Name
Vrije Universiteit Medisch Centrum
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
Facility Name
Medisch Centrum Leeuwarden
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands
Facility Name
The Memory Clinic Limited
City
Auckland
ZIP/Postal Code
0622
Country
New Zealand
Facility Name
Christchurch Hospital
City
Christchurch
ZIP/Postal Code
8011
Country
New Zealand
Facility Name
Signet Research
City
Christchurch
ZIP/Postal Code
8014
Country
New Zealand
Facility Name
Pallmed Spolka z o.o.
City
Bydgoszcz
ZIP/Postal Code
85-796
Country
Poland
Facility Name
MCD Voxel
City
Poznan
ZIP/Postal Code
60-693
Country
Poland
Facility Name
NZOZ Neuro-kard
City
Poznan
ZIP/Postal Code
61-289
Country
Poland
Facility Name
Pracownia Rezonansu Magnetycznego
City
Warszawa
ZIP/Postal Code
01-211
Country
Poland
Facility Name
SP ZOZ Szpital Wolski
City
Warszawa
ZIP/Postal Code
01-211
Country
Poland
Facility Name
Samodzielny Publiczny Centralny Szpital Kliniczny
City
Warszawa
ZIP/Postal Code
02-097
Country
Poland
Facility Name
Hospital Fernando da Fonseca
City
Amadora
State/Province
Lisboa
ZIP/Postal Code
2720-276
Country
Portugal
Facility Name
Hospitais Da Universidade De Coimbra
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Hospital Santa Maria
City
Lisboa
ZIP/Postal Code
1649-028
Country
Portugal
Facility Name
Univerzitna nemocnica Bratislava
City
Bratislava
ZIP/Postal Code
825 56
Country
Slovakia
Facility Name
Vseobecna nemocnica Rimavska Sobota
City
Rimavska Sobota
ZIP/Postal Code
979 12
Country
Slovakia
Facility Name
Boithuso Caregivers
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1709
Country
South Africa
Facility Name
The Osteoporosis and Memory Centre
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2196
Country
South Africa
Facility Name
St Augustine's Medical Centre 2
City
Durban
State/Province
Kwa Zulu Natal
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Hospital General Universitario de Elche
City
Elche
State/Province
Alicante
ZIP/Postal Code
03203
Country
Spain
Facility Name
Hospital Mutua de Terrasa
City
Terrasa
State/Province
Barcelona
ZIP/Postal Code
08221
Country
Spain
Facility Name
Hospital Virgen del Puerto
City
Plasencia
State/Province
Caceres
ZIP/Postal Code
10600
Country
Spain
Facility Name
Hospital Universitario Son Espases
City
Palma de Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07010
Country
Spain
Facility Name
CLONUS
City
Palma de Mallorca
State/Province
Islas Baleares
ZIP/Postal Code
07014
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Fundacio ACE Institut Catala de Neurociences Aplicades
City
Barcelona
ZIP/Postal Code
08014
Country
Spain
Facility Name
Clinica CIMA
City
Barcelona
ZIP/Postal Code
08034
Country
Spain
Facility Name
Hospital Divino Valles
City
Burgos
ZIP/Postal Code
09006
Country
Spain
Facility Name
Hospital de la Princesa
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital Universitario Virgen de la Arrixaca
City
Murcia
ZIP/Postal Code
30120
Country
Spain
Facility Name
Malmo University Hospital
City
Malmo
ZIP/Postal Code
21 224
Country
Sweden
Facility Name
Minnes- och geriatrikmottagningen
City
Uppsala
ZIP/Postal Code
75185
Country
Sweden
Facility Name
Memory Clinic Neuro-Psychologie Zentrum
City
Basel
State/Province
BS
ZIP/Postal Code
CH-4031
Country
Switzerland
Facility Name
Memory Service North, Grenoside Grange Hospital
City
Grenoside
State/Province
Sheffield
ZIP/Postal Code
S35 8QS
Country
United Kingdom
Facility Name
Llandough Hospital, Universtity Hospital of Wales
City
Cardiff
State/Province
Wales
ZIP/Postal Code
CF4 4XW
Country
United Kingdom
Facility Name
MAC UK Neuroscience Ltd.
City
Bradford
ZIP/Postal Code
BDQ0DQ
Country
United Kingdom
Facility Name
Clinical Investigation and Research Unit (CIRU)
City
Brighton
ZIP/Postal Code
BN2 5BE
Country
United Kingdom
Facility Name
Glasgow Memory Clinic
City
Glasgow
ZIP/Postal Code
G20 OXA
Country
United Kingdom
Facility Name
Dept. of Neurosciences Charing Cross Hospital
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom
Facility Name
The Doctors Laboratory Ltd.
City
London
ZIP/Postal Code
WIT 4EU
Country
United Kingdom
Facility Name
Newcastle General Hospital
City
Newcastle upon Tyne
ZIP/Postal Code
NE4 5PL
Country
United Kingdom
Facility Name
Northampton General Hospital
City
Northampton
ZIP/Postal Code
NN1 5BD
Country
United Kingdom
Facility Name
Royal Hallamshire Hospital
City
Sheffield
ZIP/Postal Code
S10 2JF
Country
United Kingdom
Facility Name
Victoria Hospital
City
Swindon
ZIP/Postal Code
SN3 6BW
Country
United Kingdom
Facility Name
Alliance Medical
City
Wakefield
ZIP/Postal Code
WF1 4TT
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
27334799
Citation
Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.
Results Reference
derived
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3133K1-3003&StudyName=A%20Long-Term%20Safety%20And%20Tolerability%20Extension%20Study%20Of%20Bapineuzumab%20In%20Alzheimer%20Disease%20Patients
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

We'll reach out to this number within 24 hrs